Accelerating development of a unique molecule to treat lung cancer

Learn how Syngene collaborated with a pharma company to develop the drug substance and drug product for a unique molecule to treat locally advanced lung cancer, including optimizing the process to enable commercial manufacturing of the API.

Author

Latest Blogs

Organ-on-Chip Platform: Bringing Human Biology closer to Drug Discovery and DMPK

More
Sterile fill-finish manufacturing at scale featuring automated aseptic vial filling equipment designed to reduce technology transfer risks and streamline commercial biologics production.

Sterile Fill Finish Manufacturing at Scale: How Integrated DS+DP+FF Reduces Late-Stage Surprises

More
ADC linker payload design showing an antibody drug conjugate with a cleavable linker and cytotoxic payload targeting tumor cells to improve efficacy and safety.

Why ADC Linker Payload Design Is the Real Differentiator in ADC Success

More

Why CDMO Outsourcing is Moving Earlier in Biologics Development

More
Infographic showing the shift from traditional pharma outsourcing based on cost and capacity to a new-age CRDMO model focused on scientific depth, speed, supply-chain resilience, integration, and development flexibility.

The New-Age CRDMO: Rethinking Drug Development Partnerships

More

Flow Chemistry Approaches for Poorly Soluble Pharmaceutical Intermediates

More